tadalafil · Cmp Dev Llc · NDA 214522
Tadliq
Earliest generic entry, as listed
24 Dec 2038
Blocked by patent: US 11382917, US 11666576, US 11975006, US 12186322, US 12691120, US 12697338, US 12708626, US 12721849, US 12734175.
Listed patents · 9 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11382917 | product, use U-3397 | 24 Dec 2038 |
| US 11666576 | product, use U-3397 | 24 Dec 2038 |
| US 11975006 | product, use U-3397 | 24 Dec 2038 |
| US 12186322 | product, use U-3397 | 24 Dec 2038 |
| US 12691120 | product, use U-3397 | 24 Dec 2038 |
| US 12697338 | product, use U-3397 | 24 Dec 2038 |
| US 12708626 | product, use U-3397 | 24 Dec 2038 |
| US 12721849 | product, use U-3397 | 24 Dec 2038 |
| US 12734175 | product | 24 Dec 2038 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214522 · 001 · RLD | suspension, oral | 20MG/5ML | 24 Dec 2038 |